- 2,99 €
Preamble Over the past decade, cardiac troponin (cTn)  has become the cornerstone laboratory medicine measurement for assessment of myocardial infarction (MI) in suspected acute coronary syndrome (ACS) patients. In the past 5-7 years, methods for measuring the natriuretic peptide B-type natriuretic peptide (BNP) and its inert cometabolite N-terminal proBNP (NT-proBNP) have become available, and much knowledge has accumulated regarding their clinical use in the context of heart failure and hemodynamic stress. In addition to ACS and heart failure, there are common and clinically important patient cohorts in whom these measurements can aid in diagnosis and management. For this reason, the National Academy of Clinical Biochemistry (NACB) formed a Laboratory Medicine Practice Guidelines (LMPG) committee to extend cardiac biochemical marker recommendations and establish modern guidelines for utilization in etiologies other than ACS and heart failure. During development, updated draft revisions of the guidelines were prepared and placed for comment on the NACB World Wide Web site (http://www.aacc.org/AACC/members/nacb/LMPG/OnlineGuide/ DraftGuidelines/BioHearFailure/) beginning in August 2004. The draft LMPG and suggested revisions were presented for public and stakeholder comment at the October 2004 Arnold O. Beckman Conference titled Cardiac Markers: Establishing Guidelines and Improving Results. The resulting draft guidelines can be viewed in their entirety at on the NACB World Wide Web site (http://www.aacc.org/AACC/members/nacb/LMPG/OnlineGuide/ PublishedGuidelines/ACSHeart/heartpdf.htm).